Novartis Ups The Ante In Immunotherapy With CoStim Buy
This article was originally published in The Pink Sheet Daily
The European pharma is increasing its stake in cancer immunotherapy with the acquisition of a start-up biotech that brings over late-stage assets against several targets.
You may also be interested in...
AstraZeneca and its large-molecule affiliate MedImmune will partner with Celgene to develop anti-PD-LI immune checkpoint inhibitor MEDI4736. MedImmune also signed combination trial agreements with Juno and Immunocore, while Celgene arranged to buy Quanticel and Mesoblast.
Welcome to “The Pink Sheet” DAILY’s round-up of news and notes from the first day of the 2015 J.P. Morgan Healthcare Conference in San Francisco.
Start-up companies raised $1.18 billion during the first quarter of 2014, up $2.8 million from last quarter’s total. Cancer was the leading therapy area involved in alliances.